Herzinsuffizienz und Diabetes

Matthias Rau; Michael Lehrke

doi:10.1055/a-0646-6333

Diabetes aktuell, Table of Contents

Diabetes aktuell 2018; 16(04): 148-155
DOI: 10.1055/a-0646-6333

Schwerpunkt

Kardiologie

Herzinsuffizienz und Diabetes

Therapeutische Strategien unter Berücksichtigung aktueller Studien

Matthias Rau

¹Klinik für Kardiologie, Pneumologie, Angiologie und Internistische Intensivmedizin (Medizinische Klinik I), Uniklinik RWTH Aachen, Aachen

,

Michael Lehrke

¹Klinik für Kardiologie, Pneumologie, Angiologie und Internistische Intensivmedizin (Medizinische Klinik I), Uniklinik RWTH Aachen, Aachen

› Author Affiliations

Abstract

ZUSAMMENFASSUNG

Epidemiologische und klinische Daten weisen auf eine hohe Prävalenz und Inzidenz einer Herzinsuffizienz bei Patienten mit Diabetes mellitus hin, was mit einer schlechten Prognose assoziiert ist.

Die vorliegende Übersicht fasst die therapeutischen Strategien zur Behandlung einer Herzinsuffizienz bei Patienten mit Diabetes zusammen. Des Weiteren wird die Behandlung des Diabetes bei Patienten mit Herzinsuffizienz unter Berücksichtigung der aktuellen klinischen Studien diskutiert.

Full Text

References

Literatur
1 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.. Eur J Heart Fail 2016; 18: 891-975 doi:10.1093/eurheartj/ehw128
2 Ahmad T, Pencina MJ, Schulte PJ. et al. Clinical implications of chronic heart failure phenotypes defined by cluster analysis.. J Am Coll Cardiol 2014; 64: 1765-1774 doi:10.1016/j.jacc.2014.07.979
3 Zannad F, McMurray JJ, Krum H. et al. Eplerenone in patients with systolic heart failure and mild symptoms.. N Engl J Med 2011; 364: 11-21 doi:10.1056/NEJMoa1009492
4 McMurray JJ, Packer M, Desai AS. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure.. N Engl J Med 2014; 371: 993-1004 doi:10.1056/NEJMoa1409077
5 Moss AJ, Hall WJ, Cannom DS. et al. Cardiac-resynchronization therapy for the prevention of heart-failure events.. N Engl J Med 2009; 361: 1329-1338 doi:10.1056/NEJMoa0906431
6 Swedberg K, Komaida M, Böhm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885 doi:10.1016/S0140-6736(10)61198-1
7 Look AHEAD Research Group Wing RR, Bolin P, Brancati FL. et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.. N Engl J Med 2013; 369: 145-154 doi:10.1056/NEJMoa1212914
8 Look AHEAD Research Group Gregg EW, Jakicic JM, Blackburn G. et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial.. Lancet Diabetes Endocrinol 2016; 4: 913-921 doi:10.1016/S2213-8587(16)30162-0
9 Abed HS, Wittert GA, Leong DP. et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial.. JAMA 2013; 310: 2050-2060 doi:10.1001/jama.2013.280521
10 Pathak RK, Middeldorp ME, Meredith M. et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY).. J Am Coll Cardiol 2015; 65: 2159-2169 doi: 10.1016/j.jacc.2015.03.002
11 Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.. Eur Heart J 2016; 37: 2893-2962 doi:10.1093/eurheartj/ehw210
12 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.. Lancet 1998; 352: 854-365 doi:10.1016/S0140-6736(98)07037-8
13 Aguilar D, Chan W, Bozkurt B, Ramasubbu K. et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure.. Circ Heart Fail 2011; 4: 53-58 doi:10.1161/CIRCHEARTFAILURE.110.952556
14 Evans JM, Doney AS, AlZadjali MA. et al. Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus.. Am J Cardiol 2010; 106: 1006-1010 doi:10.1016/j.amjcard.2010.05.031
15 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.. Eur Heart J 2016; 37: 2129-2200 doi:10.1093/eurheartj/ehw128
16 Boussageon R, Supper I, Bejan-Angoulvant T. et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials.. PLoS Med 2012; 9: e1001204 doi: 10.1371/journal.pmed.1001204
17 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.. Lancet 1998; 352: 837-853 doi:10.1016/S0140-6736(98)07019-6
18 Ou SM, Shih CJ, Chao PW. et al. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.. Ann Intern Med 2015; 163: 663-672 doi:10.7326/M15-0308
19 Hernandez AV, Usmani A, Rajamanickam A, Moheet A. et al. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.. Am J Cardiovasc Drugs 2011; 11: 115-128 doi:10.2165/11587580-000000000-00000
20 Scirica BM, Bhatt DL, Braunwald E. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.. N Engl J Med 2013; 369: 1317-1326 doi:10.1056/NEJMoa1307684; doi:10.1056/NEJMoa1307684
21 White WB, Cannon CP, Heller SR. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.. N Engl J Med 2013; 369: 1327-1335 doi:10.1056/NEJMoa1305889
22 Green JB, Bethel MA, Armstrong PW.. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.. N Engl J Med 2015; 373: 232-242 doi:10.1056/NEJMoa1501352
23 Scirica BM, Braunwald E, Raz I.. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.. Circulation 2014; 130: 1579-1588 doi:10.1161/CIRCULATIONAHA.114.010389
24 Pfeffer MA, Claggett B, Diaz R.. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.. Nat Rev Endocrinol 2012; 8: 728-742 doi:10.2337/ds16-0026
25 Pfeffer MA, Claggett B, Diaz R. et al. Lixisenatide in Patietnts with Type 2 Diabetes and Acute Coronary Syndrome.. N Engl J Med 2015; 373: 2247-2257 doi:10.1056/NEJMoa1509225
26 Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue.. Mol Cell Endocrinol 2009; 297: 137-140 doi:10.1016/j.mce.2008.11.018
27 Lau J, Bloch P, Schäffer L. et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.. J Med Chem 2015; 58: 7370-7380 doi: 10.1021/acs.jmedchem.5b00726
28 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.. N Engl J Med 2016; 375: 311-322 doi: 10.1056/NEJMoa1603827
29 Marso SP, Bain SC, Consoli A. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.. N Engl J Med 2016; 375: 1834-1844 doi: 10.1056/NEJMoa1607141
30 Margulies KB, Hernandez AF, Redfield MM. et al. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.. JAMA 2016; 316: 500-508 doi: 10.1001/jama.2016.10260
31 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.. N Engl J Med 2015; 373: 2117-2128 doi: 10.1056/NEJMoa1504720
32 Fitchett D, Zinman B, Wanner C. et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial.. Eur Heart J 2016; 37: 1526-1534 doi. 10.1093/eurheartj/ehv728
33 Ferrannini E, Mark M, Mayoux E.. CV Protection in the EMPA-REG OUTCOME Trial: A „Thrifty Substrate“ Hypothesis.. Diabetes Care 2016; 39: 1108-1114 doi:10.2337/dc16-0330